Gilead HIV drug not entitled to SPC, says UK court

The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate (SPC) because it failed to meet the standards set out by Europe’s highest court earlier this year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

8 January 2026 An annual, first-of-its-kind project aims to highlight the world’s leading in-house intellectual property counsel—and we need your help.

Europe

Edwards v Meril: Inside the UPC’s landmark medtech showdown

6 January 2026 As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.

Europe

Key EU and UK regulatory changes to watch for in 2026

5 January 2026 A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.

More features

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Bird & Bird targets Nordic life sciences growth with regulatory hire

Key EU and UK regulatory changes to watch for in 2026

Gilead HIV drug not entitled to SPC, says UK court

More on this story

Editor's picks

Editor's picks

More features